Retention in medication-assisted treatment for opiate dependence: A systematic review

References

• Pecoraro A, Ma M, Woody GE. The science and practice of medication-assisted treatments for opioid dependence. Subst Use Misuse 2012; 47(8–9):1026–40. doi: 10.3109/10826084.2012.663292
   Google Scholar
• UNODC. World drug report 2011. New York: United Nations Publications; 2011. 267 p. United Nations Publication Sales No. E.11.XI.10.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: Office of Applied Studies; 2011. 156 p. (DHHS Publication No. [SMA] 11-4658); (NSUDH Series H-41).
   Google Scholar
• UNODC. World drug report 2007. New York: United Nations Publications; 2007. 275 p. United Nations Publication Sales No. S.07.XI.5
   Google Scholar
• Substance Abuse and Mental Health Services Administration. National survey on drug use and health, 2010. ICPSR 32722. [Updated 2014 Sep 05; cited 2015 Mar 26]. http://www.icpsr.umich.edu/icpsrweb/SAMHDA/studies/32722-#cite (accessed March 26, 2015).
   Google Scholar
• Volkow ND, Li TK. Drug addiction: the neurobiology of behavior gone awry. Nat Rev Neurosci 2004; 5(12):963–70. doi: 10.1038/nrn1539
   Google Scholar
• World Health Organization. Neuroscience of psychoactive substance use and dependence. Geneva: World Health Organization, 2004; 264 p.
   Google Scholar
• Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10(11):1727–40. doi: 10.1517/14656560903037168
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS). ICPSR 34876. [Updated 2014 Sep 11; cited 2015 Mar 26]. http://www.icpsr.umich.edu/icpsrweb/SAMHDA/studies/34876 (acce-ssed March 26, 2015).
   Google Scholar
• Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012; 31(3):207–25. doi: 10.1080/10550887.2012.694598
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 3(CD002209). doi:10.1002/14651858.CD002209.pub2
   PubMed Web of Science ®Google Scholar
• Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend 1998; 52(3):257–60. doi: 10.1016/S0376-8716(98)00097-0
   PubMed Web of Science ®Google Scholar
• Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6(9):1049–56.
   PubMed Web of Science ®Google Scholar
• Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag, 1991; 283 p. doi: 10.1007/978-1-4613-9089-3
   Google Scholar
• Kleber, HD. Methadone maintenance 4 decades later. JAMA 2008; 300(19):2303–5. doi: 10.1001/jama.2008.648
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2(CD002207). doi: 10.1002/14651858.CD002207.pub4
   PubMed Web of Science ®Google Scholar
• Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 2006; 101(4):491–503. doi: 10.1111/j.1360-0443.2006.01369.x
   Google Scholar
• Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, Bayliss S, Roberts T, Burls A. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess 2007; 11(6): 1–85.
   Google Scholar
• Harris R, Atkins D, Berg AO, Best D, Eden KB, Feightner JW. U.S. Preventive Services Task Force procedure manual. Rockville, MD: Agency for Healthcare Research and Quality; 2008, AHRQ Publication No. 08-05118-EF.
   Google Scholar
• Petticrew M, Roberts H. Evidence, hierarchies, and typologies: horses for courses. J Epidemiol Community Health 2003; 57(7):527–9. doi: 10.1136/jech.57.7.527
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, Brooklyn MD, Higgins ST. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 2013; 70(12):1347–54. doi: 10.1001/jamapsychiatry.2013.2216
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Krupitsky E, Verbitskaya E, Blokhina E, Mamontova O, Föhr J, Tuomola P, Kuoppasalmi K, Kiviniemi V, Zwartau E. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 2012; 169(5):531–6. doi: 10.1176/appi.ajp.2011.11071121
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentere randomised trial. Lancet 2011; 377(9776):1506–13. doi: 10.1016/S0140-6736(11)60358-9
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, Burakov A, Masalov D, Romanova TN, Palatkin V, Tyurina A, Yaroslavtseva T, Sinha R, Kosten TR. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. Drug Alcohol Depend 2013; 132(3):674–80. doi: 10.1016/j.drugalcdep.2013.04.021
   PubMed Web of Science ®Google Scholar
• Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL. Buprenorphine implants for treatment of opioid dependence. JAMA 2010; 304(14):1576–83. doi: 10.1001/jama.2010.1427
   PubMed Web of Science ®Google Scholar
• Ruger JP, Chawarski M, Mazlan M, Ng N, Schottenfeld R. Cost-effectiveness of buprenorphine and naltrexone for heroin dependence in Malaysia. PLoS ONE 2012; 7(12):e50673. doi: 10.1371/journal.pone.0050673
   Google Scholar
• Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, Keruly JC, Fielin DA, Finkelstein R, Barditch-Crovo P, Cook K, Moore RD. Clinic-based treatment for opioid-dependent HIV-infected patients versus referral to an opioid treatment program. Ann Intern Med 2010; 152(11):704–11. doi: 10.1059/0003-4819-152-11-201006010-00003
   PubMed Web of Science ®Google Scholar
• Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RD, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013; 128(1–2):71–6. doi: 10.1016/j.drugalcdep.2012.08.002
   PubMed Web of Science ®Google Scholar
• Woody GE, Bruce D, Korthuis PT, Chhatre S, Poole S, Hillhouse M, Jacobs P, Sorensen J, Saxon AJ, Metzger D, Ling W. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr 2014; 66(3):288–93. doi: 10.1097/QAI.0000000000000165
   PubMed Web of Science ®Google Scholar
• Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W. Buprenorphine/naltrexone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs 2013; 74(4):605–13.
   PubMed Web of Science ®Google Scholar
• Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363(24):2320–31. doi: 1056/NEJMoa1005359
   Google Scholar
• Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Evers R, Groshkova T, Charles V, Martin A, Forzisi L. Supervised injectable heroin or injectable methadone versus optimized oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010; 375(9729):1885–95. doi: 10.1016/S0140-6736(10)60349-2
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Guh D, Marsh DC, Brissette S, Nosyk B, Krausz M, Anis A, Christian WM, Spittal P, Schechter MT. Characteristics and response to treatment among Aboriginal people receiving heroin-assisted treatment. Can J Public Health 2010; 101(3):210–2.
   PubMed Web of Science ®Google Scholar
• Nosyk B, Geller J, Guh D, Oviedo-Joekes E, Brissette S, Marsh DC, Schechter MT, Anis AH. The effect of motivation status on treatment outcome in the North American Opiate Medication Initiative (NAOMI) study. Drug Alcohol Depend 2010; 111(1–2):161–5. doi: 10.1016/j/drugalcdep.2010.03.019
   PubMed Web of Science ®Google Scholar
• Eiroa-Orosa FJ, Verthein U, Kuhn S, Lindemann C, Karow A, Haasen C, Reimer J. Implication of gender differences in heroin-assisted treatment: results from the German randomized controlled trial. Am J Addict 2010; 19(4):312–8. doi: 10.1111/j.1521-0391.2010.00049.x
   PubMed Web of Science ®Google Scholar
• Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a randomized trial. Drug Alcohol Depend 2013; 133(2):376–82. doi: 1.1016/j.drugalcdep.2013.06.024
   PubMed Web of Science ®Google Scholar
• Neumann AM, Blondell RD, Jaanimagi U, Giambrone AK, Homish GG, Lozano JR, Kowalik U, Azadfard M. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and co-existent opioid addiction. J Addict Dis 2013; 32(1):68–78. doi: 10.1080/10550887.2012.759872
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, Anis A, Schechter MT. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. J Subst Abuse Treat 2010; 38(4):408–11. doi: 10.1016/j.jsat.2010.03.003
   PubMed Web of Science ®Google Scholar
• Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J. A prospective, randomized, multicenter acceptability, and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Addiction 2011; 107(1):142–51. doi: 10.1111/j.1360-0443.2011.03577.x
   PubMed Web of Science ®Google Scholar
• Bisaga A, Sullivan MA, Chang WY, Carpenter KM, Mariani JJ, Levin FR, Raby WN, Nunes, EV. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend 2011; 119(1–2):e23–e29. doi: 10.1016/j.drugalcdep.2011.05.019
   PubMedGoogle Scholar
• Stein MD, Herman DS, Kettavong M, Cioe PA, Friedmann PD, Tellioglu T, Anderson BJ. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat 2010; 39(2):157–66. doi: 10.1016/j.sat.2010.05.014
   PubMed Web of Science ®Google Scholar
• Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, Gonsai K, Cargile C, Sofuoglu M, Chopra MP, Gonzalez-Haddad G, Carroll KM, Kosten TR. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend 2011; 113(2–3):184–91. doi: 10.1016.j.drugalcdep.2010.07.022
   PubMed Web of Science ®Google Scholar
• Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesh LZ, Dossabhoy S, Stein M. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized controlled trial. JAMA Intern Med 2014; 174(8):1369–76. doi: 10.1001/jamainternmed.2014.2556
   Google Scholar
• Chen W, Hong Y, Zou X, McLaughlin MM, Xia Y, Ling L. Effectiveness of prize-based contingency management in a methadone maintenance program in China. Drug Alcohol Depend 2013; 133(1):270–4. doi: 10.1016/j.drugalcdep.2013.05.028
   PubMed Web of Science ®Google Scholar
• Hser Y, Li J, Jiang H, Zhang R, Du J, Zhang C, Zhang B, Evans E, Wu F, Chang YJ, Peng C, Huang D, Stitzer ML, Roll J, Zhao M. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction 2011; 106(10):1801–9. doi: 10.1111/j.1360-0443.2011.03490.x
   PubMed Web of Science ®Google Scholar
• Dunn K, Defulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman, K. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Exp Clin Psychopharmacol 2013; 21(1):74–83. doi: 10.1037/a0030743
   PubMed Web of Science ®Google Scholar
• Holland R, Matheson C, Anthony G, Roberts K, Priyardarshi S, Macrae A, Whitelaw E, Appavoo S, Bond, C. A pilot randomised controlled trial of brief versus twice weekly versus standard supervised consumption in patients on opiate maintenance treatment. Drug Alcohol Rev 2012; 31(4):483–91. doi: 10.1111/j.1465-3362.2011.00394.x
   PubMed Web of Science ®Google Scholar
• Chawarski MC, Zhou W, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: a pilot randomized clinical trial. Drug Alcohol Depend 2011; 115(3):237–9. doi: 10.1016/j.drugalcdep.2010.09.024
   PubMed Web of Science ®Google Scholar
• Jaffray M, Matheson C, Bond CM, Lee AJ, McLernon DJ, Johnstone A, Skea L, Davidson B. Does training in motivational interviewing for community pharmacists improve outcomes from methadone patients? A cluster randomised controlled trial. Int J Pharm Pract 2014; 22(1):4–12. doi: 10.1111/ijpp.12049
   PubMedGoogle Scholar
• Marsch LA, Guarino H, Acosta M, Aponte-Melendez Y, Cleland C, Grabinski M, Brady R, Edwards J. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat 2014; 46(1):43–51. doi: 10.1016/j.jsat.2013.08.012
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, O'Grady KE, Gandhi D, Jaffe JH. Interim methadone treatment compared to standard methadone treatment: 4-month findings. J Subst Abuse Treat 2011; 41(1):21–9. doi: 10.1016/j.jsat.2011.01.008
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, O'Grady KE, Gandhi D, Jaffe JH. Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addiction 2012; 107(5):943–52. doi: 10.1111/j.1360-0443.2011.03700.x
   PubMed Web of Science ®Google Scholar
• Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction 2013; 108(10):1788–98. doi: 10.1111/add.12266
   PubMed Web of Science ®Google Scholar
• Mitchell SG, Gryczynski J, Schwartz RP, O'Grady KE, Olsen YK, Jaffe JH. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug Alcohol Depend 2013; 128(3):222–9. doi: 10.1016/j.drugalcdep.2012.08.027
   PubMed Web of Science ®Google Scholar
• Ruetsch C, Tkacz J, McPherson TL, Cacciola J. The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year follow-up. Addict Behav 2012; 37(5):686–9. doi: 10.1016/j.addbeh.2012.01.013
   Google Scholar
• Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat 2012; 43(4):433–9. doi: 10.1016/j.jsat.2012.07.011
   PubMed Web of Science ®Google Scholar
• Jones HE, Tuten M, O'Grady KE. Treating the partners of opioid-dependent pregnant patients: feasibility and efficacy. Am J Drug Alcohol Abuse 2011; 37(3):170–8. doi: 10.3109/00952990.2011.563336
   PubMed Web of Science ®Google Scholar
• Coviello DM, Cornish JW, Lynch KG, Alterman AI, O'Brien CP. A randomized trial of oral naltrexone for treating opioid-dependent offenders. Am J Addict 2010; 19(5):422–32. doi: 10.1111/j.1521-0391.2010.00070.x
   PubMed Web of Science ®Google Scholar
• Gryczynski J, Mitchell SG, Jaffe JH, Kelly SM, Myers CP, O'Grady KE, Olsen YK, Schwartz, RP. Retention in methadone and buprenorphine treatment among African Americans. J Subst Abuse Treat 2013; 45(3):287–92. doi: 10.1016/j.jsat.2013.02.008
   PubMed Web of Science ®Google Scholar
• Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat 2010; 39(4):340–52. doi: 10.1016/j.jsat.2010.07.009
   PubMed Web of Science ®Google Scholar
• Bounes V, Palmaro A, Lapeyre-Mestre M, Roussin A. Long-term consequences of acute pain for patients under methadone or buprenorphine maintenance treatment. Pain Physician 2013; 16:E739–E747.
   PubMed Web of Science ®Google Scholar
• Serpelloni G, Gomma M, Genetti B, Zermiani M, Rimondo C, Mollica R, Gryczynski J, O'Grady KE, Schwartz RP. Italy's electronic health record system for opioid agonist treatment. J Subst Abuse Treat 2013; 45(2):190–5. doi: 10.1016/j.jsat.2013.02.001
   PubMed Web of Science ®Google Scholar
• Hao SQ, Zhao M, Zhang RW, Zhang JC, Zhang J, Feng XS. The effectiveness comparison of Jitai tablets versus methadone in community-based drug treatment: a 1-year follow-up study. Addict Beh 2013; 38(10):2596–600. doi: 10.1016/j.addbeh.2013.05.013
   PubMed Web of Science ®Google Scholar
• Gryczynski J, Mitchell SG, Jaffe JH, O'Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients' reasons for cessation of care. J Subst Abuse Treat 2014; 46(3):356–61. doi: 10.1016/j.jsat.2013.10.004
   PubMed Web of Science ®Google Scholar
• Curcio F, Franco T, Topa M, Baldassarre C. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. Eur Rev Med Pharmacol Sci 2011; 15(8):871–4.
   PubMed Web of Science ®Google Scholar
• Miotto K, Hillhouse M, Donovick R, Cunningham-Rathner J, Charuvastra C, Torrington M, Esagoff AE, Ling W. Comparison of buprenorphine treatment for opioid dependence in 3 settings. J Addict Med 2012; 6(1):68–76. doi: 10.1097/ADM.0b013e318233d621
   PubMed Web of Science ®Google Scholar
• Gerra G, Saenz E, Busse A, Maremmani I, Ciccocioppo R, Zaimovic A, Gerra ML, Amore M, Manfredini M, Donnini C, Somaini L. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(2):483–9. doi: 10.1016/j.pnpbp.2010.12.002
   PubMed Web of Science ®Google Scholar
• Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Dep 2013; 1–2(1):127–35. doi: 10.1016/j.drugalcdep.2012.12.008
   Web of Science ®Google Scholar
• Moore BA, Barry DT, Sullivan LE, O'Connor PG, Cutter CJ, Schottenfeld RS, Fiellin DA. Counseling and directly observed medication for primary care buprenorphine maintenance. J Addict Med 2012; 6(3):205–11. doi: 10.1097/ADM.0b013e3182596492
   PubMed Web of Science ®Google Scholar
• Winklbaur-Hausknost B, Jagsch R, Graf-Rohrmeister K, Unger A, Baewert A, Langer M, Thau K, Fischer G. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Hum Psychopharmacol 2013; 28(1):15–24. doi: 10.1002/hup.2275
   PubMed Web of Science ®Google Scholar
• Knight DK, Logan SM, Simpson DD. Predictors of program completion for women in residential substance abuse treatment. Am J Drug Alcohol Abuse 2001; 27(1):1–18.
   PubMed Web of Science ®Google Scholar
• Simpson DD, Joe GW, Dansereau DF, Chatham LR. Strategies for improving methadone treatment process and outcomes. J Drug Issues 1997; 27(2):239–60.
   Web of Science ®Google Scholar
• Blanken P, Hendricks VM, van Ree JM, van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 2010; 105(2):300–8. doi: 10.1111/j.1360-0443.2009.02754.x
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney CP. QTc interval screening in methadone treatment. Ann Int Med 2009; 150(6):387–95. doi: 10.7326/0003-4819-150-6-200903170-00103
   PubMed Web of Science ®Google Scholar
• Andersen JM, Klykken C, Morland J. Long-term methadone treatment reduces phosphorylation of CaMKII in rat brain. J Pharm Pharmacol 2012; 64(6):843–7. doi: 10.111/j.2042-7158.2012.01469.x
   Google Scholar
• Whelan PJ, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract 2012; 3(1):45–50. doi: 10.4103/0976-3147.91934
   PubMedGoogle Scholar
• Perneger TV, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317(7150):13–8. doi: 10.1136/bmj.317.7150.13
   PubMed Web of Science ®Google Scholar
• van den Brink W, Hendriks VM, Blanken P, Koester MWJ, van Zwieten BJ, van Ree J. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ 2003; 327(724):310–5. doi: 10.1136/bmj.327.7410.310
   PubMed Web of Science ®Google Scholar
• Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence. Br J Psychiatry 2007; 191(1):55–62. doi: 10.1192/bjp.106.026112
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009; 361:777–86. doi: 10.1056/NEJMoa0810635
   PubMed Web of Science ®Google Scholar
• Lloyd C, McKeganey N. Drugs research: an overview of evidence and questions for policy. York, UK: Joseph Rowntree Foundation, 2010; 70 p.
   Google Scholar
• Metrebian N, Shanahan W, Wells B, Stimson GV. Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions. Med J Aust 1998; 168(12):596–600.
   PubMed Web of Science ®Google Scholar
• March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat 2006; 31(2):203–2011. doi: 10.1016/j.jsat.2006.04.007
   PubMed Web of Science ®Google Scholar
• Petitjean SA, Dursteler-MacFarland KM, Krokar MC, Strasser J, Mueller SE, Degen B, Trombini MV, Vogel M, Walter M, Wiesbeck GA, Farronato NS. A randomized, controlled trial of combined cognitive-behavioral therapy plus prize-based contingency management for cocaine dependence. Drug Alcohol Depend 2014; 145:94–100. doi: 10.1016/j.drugalcdep.2014.09.785
   PubMed Web of Science ®Google Scholar
• Rawson RA, McCann MJ, Flammino F, Shoptaw S, Miotto K, Reiber C, Ling W. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction 2006; 101(2):267–74. doi: 10.1111/j.1360-0443.2006.01312.x
   PubMed Web of Science ®Google Scholar
• Ledgerwood DM, Arfken CL, Petry NM, Alessi SM. Prize contingency management for smoking cessation: a randomized trial. Drug Alcohol Depend 2014; 140:208–12. doi: 10.1016/j.drugalcdep.2014.03.032
   PubMed Web of Science ®Google Scholar
• Benishek LA, Dugosh KL, Kirby KC, Matejkowski J, Clements NT, Seymour BL, Fetinger DS. Prize-based contingency management for the treatment of substance abusers: a meta-analysis. Addiction 2014; 109(9):1426–36. doi: 10.1111/add.12589
   Google Scholar
• Carroll KM. Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practice. Ann NY Acad Sci 2014; 1327:94–111. doi: 10.1111/nyas.12501
   PubMed Web of Science ®Google Scholar
• Guttinger F, Gschwend P, Schulte B, Rehm J, Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur Addict Res 2003; 9(2):73–9. doi: 10.1159/000068811
   PubMed Web of Science ®Google Scholar
• Skinner ML, Haggerty KP, Fleming CB, Catalano RF, Gainey RR. Opiate-addicted parents in methadone treatment: long-term recovery, health, and family relationships. J Addict Dis 2011; 30(1):17–26. doi: 10.1080/10550887.2010.531670
   PubMed Web of Science ®Google Scholar
• Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PD, Nunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ED, O'Brien CP. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus 2012; 33(1):48–59. doi: 10.1080/08897077.2011.609438.
   PubMed Web of Science ®Google Scholar
• Fox AD, Sohler NL, Starrels JL, Ning Y, Giovanniello A, Cunningham CO. Pain is not associated with worse office-based buprenorphine treatment outcomes. Subst Abus 2012; 33(4):361–5, doi: 10.1080/08897077.2011.638734.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug treatment outcomes among HIV-infected opioid dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 2011; 56(0–1):S33–S38. doi: 10.1097/QAI.0b013e3182097537.
   Google Scholar
• Apelt SM, Scherbaum N, Golz J, Backmund M, Soyka M. Safety, effectiveness, and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsychiatry 2013; 46(3):94–107. doi: 10.1055/s-0032-1330033.
   PubMed Web of Science ®Google Scholar